LAUSR

Faecal microbiota transplantation (FMT) has been used extensively in the treatment of various gastrointestinal and extra-intestinal conditions, despite that there are still a lot of missing gaps in our knowledge in the gut microbiota and its behaviour. This article describes the unknowns in microbiota biology (undetected microbes, uncertain colonization, unclear mechanisms of action, uncertain indications, unsure long-term efficacy, or side effects). We discuss how these unknowns may affect the therapeutic uses of FMT, and the potentials and caveats of other related microbiota-based therapies. When used as an experimental therapy or last resort in difficult conditions, caution should be taken against inadvertent complications. Clear documentations of post-treatment events should be made mandatory, classified and graded as in clinical trials. Further robust scientific experiments and properly designed clinical studies are needed.